- Home
- PHYS vs BMRN Comparison
PHYS vs BMRN Comparison
Compare PHYS & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHYS
- BMRN
- Stock Information
- Founded
- PHYS N/A
- BMRN 1996
- Country
- PHYS
- BMRN United States
- Employees
- PHYS N/A
- BMRN N/A
- Industry
- PHYS
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- PHYS
- BMRN Health Care
- Exchange
- PHYS NYSE
- BMRN Nasdaq
- Market Cap
- PHYS 11.9B
- BMRN 12.1B
- IPO Year
- PHYS N/A
- BMRN 1999
- Fundamental
- Price
- PHYS $25.67
- BMRN $58.00
- Analyst Decision
- PHYS
- BMRN Buy
- Analyst Count
- PHYS 0
- BMRN 22
- Target Price
- PHYS N/A
- BMRN $93.43
- AVG Volume (30 Days)
- PHYS N/A
- BMRN 2.1M
- Earning Date
- PHYS N/A
- BMRN 08-04-2025
- Dividend Yield
- PHYS N/A
- BMRN N/A
- EPS Growth
- PHYS N/A
- BMRN 152.82
- EPS
- PHYS N/A
- BMRN 2.71
- Revenue
- PHYS N/A
- BMRN $2,950,227,000.00
- Revenue This Year
- PHYS N/A
- BMRN $12.23
- Revenue Next Year
- PHYS N/A
- BMRN $9.99
- P/E Ratio
- PHYS N/A
- BMRN $21.48
- Revenue Growth
- PHYS N/A
- BMRN 19.36
- 52 Week Low
- PHYS N/A
- BMRN $52.93
- 52 Week High
- PHYS N/A
- BMRN $94.85
- Technical
- Relative Strength Index (RSI)
- PHYS 49.37
- BMRN 59.75
- Support Level
- PHYS $25.17
- BMRN $56.76
- Resistance Level
- PHYS $25.61
- BMRN $59.98
- Average True Range (ATR)
- PHYS 0.21
- BMRN 1.44
- MACD
- PHYS -0.05
- BMRN 0.62
- Stochastic Oscillator
- PHYS 47.92
- BMRN 81.47
About PHYS SPROTT PHYSICAL GOLD TRUST
Sprott Physical Gold Trust is a closed-end mutual fund trust. The company provides a secure, convenient and exchange-traded investment alternative for investors interested in holding physical gold bullion without the inconvenience associated with direct investment in physical gold bullion. The company invests mainly in long-term holdings of unencumbered, fully allocated, physical gold bullion and does not and will not speculate about short-term changes in gold prices.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.